Development of a hepatitis C virus relapse model using genome-length hepatitis C virus ribonucleic acid-harboring cells possessing the interferon-α-resistance phenotype

Hepatology Research

Volumn 39, Issue 9, 2009, Pages 898-909

  Kawai, Yoshinari ^a   Ikeda, Masanori ^a   Abe, Ken Ichi ^a   Yano, Masahiko ^a,b   Ariumi, Yasuo ^a   Dansako, Hiromichi ^a   Yamamoto, Kazuhide ^a   Kato, Nobuyuki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Cyclosporine A; Hepatitis C virus; Interferon ; Interferon ; Statin

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYCLOSPORIN A; FLUINDOSTATIN; GAMMA INTERFERON; VIRUS RNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENOME ANALYSIS; HEPATITIS C; HEPATITIS C VIRUS; INFECTION PREVENTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RELAPSE; RNA REPLICATION; VIRUS GENOME;

EID: 69949091319     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00525.x     Document Type: Article

References (36)

1. Liang TJ, Jeffers LJ, Reddy KR et al. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 1993; 18: 1326-33.
2. Kato N, Hijikata M, Ootsuyama Y et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87: 9524-8.
3. Tanaka T, Kato N, Cho MJ, Shimotohno K. A novel sequence found at the 3′ terminus of hepatitis C virus genome. Biochem Biophys Res Commun 1995; 215: 744-9.
4. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA 1991; 88: 5547-51.
5. Hijikata M, Mizushima H, Tanji Y et al. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc Natl Acad Sci USA 1993; 90: 10773-7.
6. Kato N. Molecular virology of hepatitis C virus. Acta Med Okayama 2001; 55: 133-59.
7. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 2003; 77: 3181-90.
8. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun 2005; 329: 1350-9.
9. Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002; 76: 2997-3006.
10. Kato N, Sugiyama K, Namba K et al. Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro. Biochem Biophys Res Commun 2003; 306: 756-66.
11. Kishine H, Sugiyama K, Hijikata M et al. Subgenomic replicon derived from a cell line infected with the hepatitis C virus. Biochem Biophys Res Commun 2002; 293: 993-9.
12. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-3.
13. Mori K, Abe K, Dansako H, Ariumi Y, Ikeda M, Kato N. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C. Biochem Biophys Res Commun 2008; 371: 104-9.
14. Yokota T, Sakamoto N, Enomoto N et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 2003; 4: 602-8.
15. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-6.
16. Naka K, Ikeda M, Abe K, Dansako H, Kato N. Mizoribine inhibits hepatitis C virus RNA replication: Effect of combination with interferon-alpha. Biochem Biophys Res Commun 2005; 330: 871-9.
17. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44: 117-25.
18. Kim SS, Peng LF, Lin W et al. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology 2007; 132: 311-20.
19. Ikeda M, Kato N. Modulation of host metabolism as a target of new antivirals. Adv Drug Deliv Rev 2007; 59: 1277-89.
20. Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: Suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci 2007; 105: 145-50.
21. Namba K, Naka K, Dansako H et al. Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype. Biochem Biophys Res Commun 2004; 323: 299-309.
22. Noguchi T, Otsubaki T, Ando I, Ogura N, Ikeda S, Shimotohno K. Isolation and gene analysis of interferon alpha-resistant cell clones of the hepatitis C virus subgenome. Virology 2008; 375: 424-32.
23. Akuta N, Suzuki F, Kawamura Y et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-10.
24. Dansako H, Naganuma A, Nakamura T, Ikeda F, Nozaki A, Kato N. Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element. Virus Res 2003; 97: 17-30.
25. Inoue K, Umehara T, Ruegg UT et al. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 2007; 45: 921-8.
26. Kapadia SB, Chisari FV Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005; 102: 2561-6.
27. Nakagawa M, Sakamoto N, Tanabe Y et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 2005; 129: 1031-41.
28. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-8.
29. Ye J, Wang C, Sumpter R et al. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 2003; 100: 15865-70.
30. Naka K, Abe K, Takemoto K et al. Epigenetic silencing of interferon-inducible genes is implicated in interferon resistance of hepatitis C virus replicon-harboring cells. J Hepatol 2006; 44: 869-78.
31. Naka K, Takemoto K, Abe K et al. Interferon resistance of hepatitis C virus replicon-harbouring cells is caused by functional disruption of type I interferon receptors. J Gen Virol 2005; 86: 2787-92.
32. Sumpter R Jr, Wang C, Foy E, Loo YM, Gale M Jr. Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J Virol 2004; 78: 11591-604.
33. Zhu H, Nelson DR, Crawford JM, Liu C. Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance. J Interferon Cytokine Res 2005; 25: 528-39.
34. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
35. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 2008; 48: 38-47.
36. Abe K, Ikeda M, Dansako H, Naka K, Kato N. Cell culture-adaptive NS3 mutations required for the robust replication of genome-length hepatitis C virus RNA. Virus Res 2007; 125: 88-97.